Science · Health
Red light: what it really does, and what is just marketing
Light therapy is in fashion and the lamps sell themselves. The evidence says it works for a few very specific things, and barely at all for almost everything else.
Search for “red light” and you will find everything: that it rejuvenates the skin, that it burns fat, that you will sleep better, that it gives you energy, that it cures almost anything. Behind all that sits a real technique with a serious name (photobiomodulation) and dozens of devices on sale. The useful question is not whether it “works”, but what it works for and what it doesn’t.
Photobiomodulation uses red light (around 620-700 nanometres) and near infrared (around 700-1,440 nanometres), delivered by LED or low-level laser. It has solid clinical evidence for a few specific uses, and very little for almost everything the advertising promises.
Where the evidence is real
Its strongest backing is for the side effects of cancer treatment. The MASCC/ISOO guideline of 2019 recommends it to prevent oral mucositis (the mouth sores caused by chemotherapy and radiotherapy) in three groups of patients: haematopoietic stem cell transplantation, head and neck radiotherapy without chemotherapy, and head and neck radiotherapy with chemotherapy. For treating mucositis once it has set in, or mucositis caused by chemotherapy, it makes no recommendation, for lack of evidence. The 2024 review in IJMS counts radiation dermatitis, the skin damage caused by radiotherapy, among the best-studied uses in dermatology, alongside mucositis. For chronic wounds, the same review notes that there are relatively few rigorous studies, and the international diabetic foot guideline (IWGDF, 2023) recommends not using physical therapies, light and laser among them, to heal diabetic foot ulcers: of the eight light or laser studies it reviewed, only three measured whether the wound closed, and their results were conflicting. For acne, a 2016 Cochrane review concluded that high-quality evidence on light therapies is lacking. The trial by Goldberg and Russell (2006, twenty-four patients) had no control group and did not test red light on its own, but blue light at 415 nanometres alternated with red at 633. Since photobiomodulation is defined by red and near infrared, that result cannot be credited to it in full. For skin rejuvenation there is one controlled trial with positive results (Wunsch and Matuschka, 2014). The evidence is patchier and the protocols less standardised, so it should not be sold as settled. There is also reasonable support in hair loss and positive results in some trials on joint and muscle pain, where the evidence is clearly more limited.
Where it is oversold
The jump from “it works on skin” to “it works on everything” is pure marketing. The generic wellness uses (burning fat, “detox”, energy) have no solid backing, though the bag is worth separating out: in 2010 the US Food and Drug Administration authorised a low-level laser for body contouring through the De Novo route, so “no evidence at all” would be false. That said, the authorisation is for reducing the circumference of the hips, waist and thighs, on prescription, not for weight loss, and for “detox” and “energy” there is neither an authorisation nor a systematic review to back them.
Does it work? Level of evidence, use by use
Degree of clinical evidence for photobiomodulation (red light / near infrared), use by use.
| Use | Evidence | Type of light | Note |
|---|---|---|---|
| Prevention of oral mucositis (haematopoietic stem cell transplantation, head and neck radiotherapy) | Solid | Red/NIR | The MASCC/ISOO 2019 guideline recommends it in three groups of patients; no recommendation for treating mucositis |
| Hair loss (alopecia) | Moderate | Red/NIR | Positive results, less consistent |
| Healing of wounds and ulcers | Limited | Red/NIR | The IWGDF 2023 guideline recommends not using it to heal diabetic foot ulcers |
| Acne | Limited | Blue 415nm + red 633nm, combined | Cochrane 2016: high-quality evidence is lacking. The Goldberg and Russell trial alternates the two colours and had no control group |
| Skin rejuvenation | Limited | Red/NIR | One controlled trial with positive results |
| Joint and muscle pain | Limited | NIR 700-1,440nm | Positive in some trials |
| “Fat burning” / detox / energy | Very limited | Low-level laser | The FDA authorised a body-contouring device in 2010; “detox” and “energy” have no backing |
| Night-time light for sleeping | Limited (different use) | Red/amber, ambient | Not photobiomodulation. In Figueiro and Rea 2010, red light at night did not lower melatonin; blue light did |
Source: the rating is the author’s own, based on these sources. Mucositis: MASCC/ISOO 2019 guideline. Hair loss: JAAD 2024 (CME review of photobiomodulation, part II) and the meta-analysis by Alahmadi et al. 2026. Wounds: IWGDF 2023 guideline (recommendation 15) and the IJMS 2024 review. Acne: Cochrane review 2016 and Goldberg and Russell 2006 (PMID 16766484), which alternates blue at 415 nm and red at 633. Rejuvenation: Wunsch and Matuschka 2014. Pain: meta-analyses by Chow et al. 2009 and Stausholm et al. 2019. “Fat burning”: the FDA De Novo file DEN090008, granted on 24 August 2010, which authorises the device to reduce the circumference of the hips, waist and thighs, not for weight loss. Night-time light: Figueiro and Rea 2010. Wavelength ranges: JAAD 2024, part I.
The use that almost holds up: light at night
There is one use that never appears in the medical reviews of light therapy and that is worth looking at separately: the light in your house at night. Our body clock is set by the light that reaches the eyes, and blue light (the light of screens and of many LED bulbs) is the one that most suppresses melatonin, the hormone that prepares the body for sleep. The field’s two canonical studies —Brainard and Thapan, both from 2001— place the strongest effect between 446 and 477 nanometres and at around 459, respectively. Red or amber light, by its wavelength, should affect it far less, but those two studies never measured it: their ranges stop at 600 and 548 nanometres. Red light was measured by Figueiro and Rea in 2010, with twelve people: an hour of red light at night did not lower melatonin, and an hour of blue light did. So swapping the hard, bluish lights of the last hours of the day for a soft red lamp is not a treatment: it is, quite simply, not sabotaging your own rest. Mind the distinction: this is ambient light, not a clinical dose or a “therapy” panel for the skin.
What separates one from the other
There is an enormous difference between a clinical use (a medical device, with a measured dose and measured parameters, applied to a specific indication) and a consumer gadget that promises everything and specifies nothing. If you are thinking of buying one, the question is not “does red light work?”, but “for my particular problem, and at what dose?”.
Red light is neither a scam nor a miracle: it is a tool with real, narrow uses that fashion has stretched to the absurd. Knowing what it is good for is also knowing what it isn’t.
Correction · 4 November 2026
What has been corrected
Wavelength ranges: the piece said 630-700 nanometres for red light and 780-1,100 for near infrared. The JAAD review it cites gives 620-700 and 700-1,440.
Wounds and ulcers: rated as “Solid” evidence. The IWGDF 2023 guideline recommends not using light or laser to heal diabetic foot ulcers. Now “Limited”.
Mucositis: rated as “Solid” in general. The MASCC/ISOO 2019 guideline recommends it only to prevent mucositis in three groups of patients, not to treat it.
Acne: rated as “Moderate”, with the Goldberg and Russell trial presented as “the reference trial”. The 2016 Cochrane review concludes that high-quality evidence is lacking, and that trial had no control group. Now “Limited”.
Rejuvenation: it sat in the acne row as “Moderate”, with no source of its own. It now has its own row and source, one controlled trial, and is rated “Limited”.
Red light at night: the piece said it had not been measured. Figueiro and Rea measured it in 2010, and it did not lower melatonin.
Blue light: the piece put its peak at 460-480 nanometres. The sources give 446-477 (Brainard) and 459 (Thapan).
FDA: the piece said the 2010 authorisation was not a demonstration of efficacy. The FDA authorised the device to reduce the circumference of the hips, waist and thighs, with reasonable assurance of safety and effectiveness for that use; not for weight loss.
Evidence scale: it was attributed to the JAAD and IJMS reviews. It is the author’s own, and each row now carries its source.
Sources list: the two reviews were labelled as primary sources. A “commercial reference page” with no name or address has been removed, along with a sentence about figures on blogs that did not identify those blogs.
Until 2 September 2026 this piece published a Chart 2 with percentages of melatonin suppression by colour of light (blue 100%, green or white 55%, red or amber 15%) that had no source. It was taken down that day with a visible note, and that note was deleted on 19 September.
Sources, consulted on 4 November 2026: PubMed abstracts (PMID 38309304, 31286228, 37232034, 27670126, 16766484, 24286286, 11487664, 11507175 and 20652045), the full text of the IJMS review (PMC11049838), the IWGDF 2023 guideline as a PDF and the FDA classification order K082609.
Sources
- Maghfour J et al., “Photobiomodulation CME part I: Overview and mechanism of action”, and Mineroff J et al., “Photobiomodulation CME part II: Clinical applications in dermatology”, Journal of the American Academy of Dermatology 2024;91(5):793-802 and 805-815, PMID 38309304 and 38307144 — continuing medical education review, in two parts. Part I gives the ranges: red, 620-700 nm; near infrared, 700-1,440 nm.
- Hernández-Bule ML, Naharro-Rodríguez J, Bacci S, Fernández-Guarino M, “Unlocking the Power of Light on the Skin: A Comprehensive Review on Photobiomodulation”, International Journal of Molecular Sciences 2024;25(8):4483, PMID 38674067 — narrative review.
- Zadik Y et al., Mucositis Study Group of MASCC/ISOO, “Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines”, Supportive Care in Cancer 2019;27(10):3969-3983, PMID 31286228 — systematic review and clinical guideline.
- Chen P et al., “Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update)”, Diabetes/Metabolism Research and Reviews 2024;40(3):e3644, PMID 37232034 — clinical guideline, recommendation 15.
- Barbaric J et al., “Light therapies for acne”, Cochrane Database of Systematic Reviews 2016, CD007917.pub2, PMID 27670126 — systematic review: 71 trials.
- Goldberg DJ, Russell BA, “Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris”, J Cosmet Laser Ther 2006;8(2):71-75, PMID 16766484. Twenty-four patients recruited; twenty-two finished. No control group. This is the trial behind the acne row, and it alternates the two colours.
- Wunsch A, Matuschka K, “A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase”, Photomedicine and Laser Surgery 2014;32(2):93-100, PMID 24286286 — controlled trial.
- Alahmadi M et al., “Lasers and Energy-Based Devices in the Treatment of Androgenetic Alopecia: A Systematic Review and Meta-Analysis”, Skin Appendage Disorders, published online in May 2026, PMID 42339398 — meta-analysis.
- Chow RT et al., “Efficacy of low-level laser therapy in the management of neck pain”, The Lancet 2009;374(9705):1897-1908, PMID 19913903; and Stausholm MB et al., “Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis”, BMJ Open 2019;9(10):e031142, PMID 31662383 — meta-analyses. The latter notes that the major knee osteoarthritis guidelines do not recommend this therapy.
- FDA, De Novo database, file DEN090008 (associated 510(k) number K082609): “fat reducing low level laser”, Erchonia ML Scanner, decision granted on 24 August 2010, regulation 878.5400. Authorised, on prescription, to reduce the circumference of the hips, waist and thighs.
- Brainard GC et al., “Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor”, The Journal of Neuroscience 2001;21(16):6405-6412, DOI 10.1523/jneurosci.21-16-06405.2001; and Thapan K, Arendt J, Skene DJ, “An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans”, The Journal of Physiology 2001;535(1):261-267, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x. These are the field’s two canonical action spectra: neither measured red or amber light.
- Figueiro MG, Rea MS, “The effects of red and blue lights on circadian variations in cortisol, alpha amylase, and melatonin”, International Journal of Endocrinology 2010:829351, PMID 20652045. Twelve people; only blue light lowered nocturnal melatonin.